Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...
Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...